Jun. 29 at 4:23 PM
$ICCM broke my rules and still in this because cryoablation for NIBC has lower recurrence rate, better aesthetics, less invasive, etc. Wondering why stock price still hasn’t taken off when it’s approved all over the world. Yes, FDA label is narrow(age 70+). Yes, other tumor types also look good. Yes, flexible wand and newest machine all good innovations. So why isn’t this getting any love? Was hoping MDT/BSX would be looking at it. Perhaps leadership is the problem?
